Trial
NCT02671942
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
—
Condition
Chronic Obstructive Pulmonary Disease
Intervention
Roflumilast
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-21